MetaCap

Neuphoria Therapeutics Inc. Company Profile

NASDAQ: NEUPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.35+0.03 (+1.29%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Neuphoria Therapeutics at a glance

Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Millis, MA. Neuphoria Therapeutics is led by Dr. Spyridon Papapetropoulos M.D., Ph.D. and employs about 1 people. The company's shares have traded publicly since 2021.

At a market capitalization of $12.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001191070, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Neuphoria Therapeutics do?

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Neuphoria Therapeutics Inc.
Ticker
NASDAQ: NEUP
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Employees
1
Headquarters
14 Milliston Road, Millis, MA, United States
Phone
339 240 6066
IPO year
2021
Market cap
$12.50M
SEC CIK
0001191070
Latest annual report
10-K · Sep 18, 2026

Companies similar to Neuphoria Therapeutics

NEUP peer companies
CompanyPrice% ChgMarket capCompare
ALLRAllarity Therapeutics Inc.0.785-9.25%$12.56Mvs NEUP
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs NEUP
MIRAMIRA Pharmaceuticals Inc.0.291-20.84%$12.23Mvs NEUP
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs NEUP
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs NEUP
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs NEUP
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs NEUP
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs NEUP

Related